medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2007, Número 1

<< Anterior Siguiente >>

Rev Mex Urol 2007; 67 (1)


Nuevos conceptos en el tratamiento de los síntomas de vejiga hiperactiva asociados a obstrucción del vaciamiento vesical secundario a crecimiento prostático benigno

Feria BG

Idioma: Español
Referencias bibliográficas: 21
Paginas: 49-55
Archivo PDF: 114.05 Kb.


RESUMEN

La nueva terminología empleada para los síntomas urinarios bajos nos permite clasificarlos con más precisión; los secundarios a la obstrucción del vaciamiento vesical, suelen mejorar con el empleo de alfabloqueadores; sólo cuando la glándula prostática es mayor a 40g se recomienda asociar al tratamiento el uso de inhibidores de la 5 alfa-reductasa. La hiperactividad del músculo detrusor primaria o secundaria a obstrucción del vaciamiento vesical, puede manifestarse clínicamente como vejiga hiperactiva, en cuyo caso la administración de antimuscarínicos es adecuada, particularmente cuando el volumen de orina residual es moderado. El riesgo potencial de desencadenar retención aguda de orina con estos fármacos no ha sido confirmado en estudios clínicos realizados, concluyendo que su empleo es seguro y eficaz.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of coger urinary tract function: report from the Standaridisation Sub-committee of the Internacional Continent Society. Nuerourol Urodyn. 2002;21:167-78.

  2. Abrams PH., Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic análisis of 152 patients. J Urol. 1979;121:640-42.

  3. Knutson T, Schafer W, Fall M, Petterson S annd Dahlstrand C. Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting? – A four-year follow-up study. Scand J Urol Nephrol. 2001;35:463-9.

  4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J and Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87:760-66 (Erratum: BJU Int. 2001;88:807).

  5. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49.

  6. Hyman MJ, Groutz A and Blaivas JG. Detrusor inestability in men: correlation of lower urinary tract symptoms with urodynamic finding. J Urol. 2001; 166:550-52.

  7. Sahai A, Shamim Khan M, Arya M, Jhon J, Singh R and Patel H. The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. Expert Opin Pharmacother. 2006;7(5):509-27.

  8. Groat W. A neurologic basis for overactive bladder. Urology. 1997:50(6A):36-52.

  9. Kyprianou Natasha. Doxazosin and terazosin supress prostate growth by inducing apoptosis: clinical significance. J Urol. 2003;169:1520-25.

  10. Feria-Bernal Guillermo, Castillejos MR. Manejo de la hipertrofia prostática benigna. Rev Mex Urol. 2004; 64(6):283-87.

  11. AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations. AUA Practice Guidelines Committee. J Urology. 2003;170(2):530-47.

  12. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5 alfa- reductase inhibitor dutasteride: results of 4 year studies. BJU Int. 2005;96:572-77.

  13. Schulman C, Pommerville P, Hofner K, Wachs B. Long- term therapy with the dual 5 alpha- reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int. 2006;97:73-80.

  14. Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette, Porru D, Thuroff JW. The International Continence Society “Benign Prostatic Hyperplasia” study: the botherosomeness of urinary symptoms. J Urol. 1997; 157(3):885-89.

  15. Abrams P, Kaplan S and Millard R. Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO). Neurol Urodyn. 2001;20(Suppl):547-48.

  16. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P and Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169:2253-56.

  17. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ and Chancellor MB. Comparison of doxazosin wiith or without tolterodine in men with symptomatisch bladder outlet obstruction and an overactieve bladder . BJU Int. 2004;94:817-20.

  18. Kaplan S, Walmsley K and Te A. Tolterodine extended release attenuates lower urinary tract symptom in men with benign prostatic hyperplasia. J Urol. 2005; 174:2273-76.

  19. Abrams P, Kaplan S, De Koning Gans H and Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175:999-1004.

  20. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride and oxybutinin on the central nervous system. J Clin Pharmacol. 2001; 41:636-44.

  21. Chapple Ch R and Roehrborn Claus G. A shifted paradigm for the further understanding, evaluation and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651-59.




2020     |     www.medigraphic.com